We provide pharmacy benefits management, PBM, Ancillary Medical, Durable Medical Equipment and Compound Pharmacy. myMatrixx is open 24 hours a day 7 days a week 365 days a year.
Check out the conversation on Joe Paduda's blog and the comments from myMatrixx's Chief Clinical Officer, Phil Walls. http://www.joepaduda.com/archives/002290.html#comments
Steve MacDonald, CEO of myMatrixx is interviewed by ABC Action News on the recent failure of the re-packaging bill to pass in Florida and the impact on the industry. Check out the story that ran last night.
Congratulations to the myMatrixx IT Team for being named the winner of the IT Dream Team Category at the BizTech Awards hosted by the Tampa Bay Technology Forum and the Tampa Bay Business Journal. Thanks for everything you do to make us look good!
The FDA's MedWatch program released new safety information for patient and prescribers of Zofran® (generic-ondansetron). Ondansetron is FDA approved for prevention of cancer chemotherapy-induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and prevention of postoperative nausea and/or vomiting.
Some recognized off-label uses include, alcohol consumptions/effects, bulimia, cholestatic pruritus, nausea and vomiting in palliative care, tardive dyskinesia, uremic pruritus, and treatment of vomiting associated with N-acetylcysteine use. Ondansetron is often used in pain management for opioid-induced nausea.
Ondansetron may cause a cardiac condition known as QT interval prolongation. This is fundamentally a disruption of normal heart rhythm leading to development of arrhythmias. The most severe form of cardiac arrhythmias is known as Torsade de Pointes which can be fatal.
Patients at increased risk of developing Torsade de Pointes from the use of Zofran® may have existing congenital QT interval prolongation. It is recommended to avoid the use of Zofran® in these patients.
It is recommended to monitor cardiac rhythm (ECG) in patients on Zofran® who have electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or in patients taking other medication known to also cause QT prolongation such as: methadone, amiodarone, haloperidol, Abilify®, and others.
Upon learning of this situation, the myMatrixx clinical team began to immediately review our entire client population for patients that are affected. At this point, we are informing all prescribers of Ondansetron and providing sufficient information to identify the level of risk and help guide the selection of suitable alternatives.
For more information read the FDA MedWatch safety alert, including a link to the Drug Safety Communication here.
myMatrixx Ranks On Inc. 500|5000 As One of the Nation's Fastest-Growing Pharmacy Benefit Managers and Private Companies
Ranks No. 1918 with Three-Year Sales Growth of 135%
TAMPA, August 29, 2011 -- Inc. magazine today ranked myMatrixx No. 1918 on its fifth annual Inc. 500|5000, an exclusive ranking of the nation's fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy - America’s independent entrepreneurs. Online retailer ideeli tops this year’s list. myMatrixx joins Spirit Airlines, television maker Vizio, Honest Tea, Dunkin Donuts and Metrokane, makers of the Rabbit corkscrew, among other prominent brands featured on this year’s list. myMatrixx also ranked No. 155 on the list of Top Health Companies on the Inc. 5000.
“We are honored to once again be included on the Inc. 500|5000,” commented Steve MacDonald, Chairman and CEO of myMatrixx. “We are among a great group and to be considered one of America’s fastest-growing companies is an accomplishment we are extremely proud of,” added MacDonald.
In a stagnant economic environment, median growth rate of 2011 Inc. 500|5000 companies remains an impressive 94 percent. The companies on this year’s list report having created 350,000 jobs in the past three years, and aggregate revenue among the honorees reached $366 billion, up 14 percent from last year.
Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/5000.
"Now, more than ever, we depend on Inc. 500/5000 companies to spur innovation, provide jobs, and drive the economy forward. Growth companies, not large corporations, are where the action is,” says Inc. magazine Editor Jane Berentson.
The 2011 Inc. 500|5000 is ranked according to percentage revenue growth when comparing 2007 to 2010. To qualify, companies must have been founded and generating revenue by March 31, 2007. Additionally, they had to be U.S. based, privately held, for profit, and independent. The minimum revenue required for 2007 is $100,000; the minimum for 2010 is $2 million.
For more information on myMatrixx, please contact Lori Taylor, Director of Marketing and Communications at (813) 321-1317. Click here to read the full release.
# # #
About myMatrixx
myMatrixx is a full-service pharmacy and ancillary medical benefits management company focusing on the “Customer Experience.” The company’s Technology Plus™ platform and approach combines advanced technology, expert clinical support, productivity-improving processes, real-time alerts and comprehensive reporting to simplify the management of worker’s compensation claims. The result is a reduction of costs and improved outcomes for clients and their injured workers. For more information visit us at www.mymatrixx.com.
About Inc. Magazine
Founded in 1979 and acquired in 2005 by Mansueto Ventures LLC, Inc. (www.inc.com) is the only major business magazine dedicated exclusively to owners and managers of growing private companies that delivers real solutions for today’s innovative company builders. With a total paid circulation of 710,106, Inc. provides hands-on tools and market-tested strategies for managing people, finances, sales, marketing, and technology. Visit us online at www.inc.com.
|
|
|
